title: Transcriptional regulation of insulin-like growth factor-binding protein-5 by prostaglandin E2 in osteoblast cells.
abstract: Insulin-like growth factor (IGF)-binding protein-5 (IGFBP-5) is an autocrine and paracrine factor that modulates the effects of IGFs. We examined the mechanisms that regulate IGFBP-5 synthesis by PGE2 in osteoblast-enriched cells from fetal rat calvaria (Ob cells). PGE2 at 1 microM for 2-8 h increased IGFBP-5 heterogeneous nuclear RNA levels and did not change the half-life of IGFBP-5 messenger RNA in Ob cells, suggesting that PGE2 stimulates IGFBP-5 transcription. To analyze the elements responsible for this effect, regions of the mouse IGFBP-5 promoter from -2695 to +120 bp were ligated into pGL-2-basic and transiently transfected into Ob cells. PGE2 caused a time- and dose-dependent increase in IGFBP-5 promoter activity. Further analysis revealed two potential PGE2-responsive regions in the -2695 to -1470 and the -989 to -332 fragments. The effect of PGE2 on IGFBP-5 messenger RNA and heterogeneous nuclear RNA levels was mimicked by forskolin and inhibited by the PKA inhibitor H-89, suggesting that part of the PGE2 effect was mediated through a cAMP-dependent pathway. H-89 also blocked basal and PGE2-stimulated IGFBP-5 promoter activities. We conclude that PGE2 regulates IGFBP-5 synthesis in Ob cells by transcriptional mechanisms. PKA-dependent pathways account for part of the effect of PGE2 on IGFBP-5 expression. Deletion analysis of the IGFBP-5 promoter suggests the presence of two PGE2-responsive regions.
authors.affiliation: Department of Research, Saint Francis Hospital and Medical Center, Hartford, Connecticut 06105, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Pash
authors.forename: E
authors.initials: E
authors.lastname: Canalis
mesh_terms: D000818:Animals; D001483:Base Sequence; D001842:Bone and Bones / Q000196:embryology; D002478:Cells, Cultured; D005576:Colforsin / Q000494:pharmacology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D015232:Dinoprostone / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D018975:Insulin-Like Growth Factor Binding Protein 5 / Q000235:genetics*; D007546:Isoquinolines / Q000494:pharmacology; D008969:Molecular Sequence Data; D010006:Osteoblasts / Q000378:metabolism*; D011247:Pregnancy; D011401:Promoter Regions, Genetic; D011493:Protein Kinase C / Q000378:metabolism; D012332:RNA, Heterogeneous Nuclear / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D013449:Sulfonamides; D014158:Transcription, Genetic / Q000187:drug effects*
chemical_list: D004791:Enzyme Inhibitors; D018975:Insulin-Like Growth Factor Binding Protein 5; D007546:Isoquinolines; D012332:RNA, Heterogeneous Nuclear; D012333:RNA, Messenger; D013449:Sulfonamides; D005576:Colforsin; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C; D015232:Dinoprostone; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide